4d Molecular Therapeutics Inc   (FDMT)
Other Ticker:  
Price: $29.3700 $1.35 4.818%
Day's High: $29.91 Week Perf: 1.28 %
Day's Low: $ 27.65 30 Day Perf: 70.26 %
Volume (M): 865 52 Wk High: $ 35.61
Volume (M$): $ 25,417 52 Wk Avg: $17.34
Open: $28.77 52 Wk Low: $9.44

 Market Capitalization (Millions $) 1,241
 Shares Outstanding (Millions) 42
 Employees -
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -96
 Cash Flow (TTM) (Millions $) 268
 Capital Exp. (TTM) (Millions $) 2

4d Molecular Therapeutics Inc
4D Molecular Therapeutics Inc is a biotechnology company that focuses on developing gene therapies for the treatment of serious genetic diseases. The company utilizes an innovative approach called targeted gene therapy, which involves delivering therapeutic genes directly to specific cells in the body. This approach has the potential to provide more effective and precise treatments for a wide range of genetic disorders.

4D Molecular Therapeutics Inc has developed a proprietary Adeno-Associated Virus (AAV) vector platform that enables the targeted delivery of therapeutic genes to specific organs, tissues, and cell types. This platform allows for precise control over the delivery and expression of therapeutic genes, minimizing the risk of off-target effects and enhancing the efficacy of the treatment.

The company is actively involved in preclinical and clinical studies to evaluate the safety and effectiveness of their gene therapies. They are working on developing treatments for diseases such as cystic fibrosis, Duchenne muscular dystrophy, and Fabry disease.

4D Molecular Therapeutics Inc collaborates with leading academic institutions, biopharmaceutical companies, and patient advocacy groups to accelerate the development of their gene therapies. They are committed to advancing the field of gene therapy and improving the lives of patients suffering from genetic diseases.

   Company Address: 5858 Horton Street #455 Emeryville 94608 CA
   Company Phone Number: 505-2680   Stock Exchange / Ticker: NASDAQ FDMT
   FDMT is expected to report next financial results on March 14, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Promising Interim Data from 4D Molecular Therapeutics' 4D-310 Phase 1/2 Trials for Fabry Disease Cardiomyopathy Presented at WORLD Symposium 2024

Published Mon, Feb 12 2024 1:01 PM UTC

4D Molecular Therapeutics (4DMT), a pioneering clinical-stage genetic medicines company, shared updated interim safety and efficacy data on their investigational therapy, 4D-310, for the treatment of Fabry disease cardiomyopathy. The data were presented at the prestigious WORLD Symposium 2024 in San Diego, California. Fabry disease is a rare genetic disorder characterized by...


4D Molecular Therapeutics Raises $300 Million in Upsized Public Offering

Published Wed, Feb 7 2024 4:27 AM UTC

4D Molecular Therapeutics Raises Approximately $300 Million in Upsized Public Offering
EMERYVILLE, Calif., Feb. 06, 2024 - 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage genetic medicines company, has successfully priced an upsized underwritten public offering of its common stock, raising approximately $300 million in gross proceeds.
The offering in...

Stock Market Announcement

4D Molecular Therapeutics Pioneers Cutting-Edge Genetic Medicines with Commencement of $250 Million Public Offering

Published Mon, Feb 5 2024 9:05 PM UTC

4D Molecular Therapeutics Announces Commencement of $250 Million Public Offering of Common Stock
EMERYVILLE, Calif., Feb. 05, 2024 - 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company, has unveiled plans to begin an underwritten public offering of $250.0 million of its common stock. The company aims to utilize the funds to ...

Clinical Study

4D Molecular Therapeutics Charting a Path in Genetic Medicine with Robust PRISM Trial Results and Healthy Financial Growth

Published Sat, Feb 3 2024 10:00 PM UTC

As the globe continues to battle a range of diseases, advancements made in the field of genetic medicines have been critical in altering the course of disease management. In cognizance of this, 4D Molecular Therapeutics, a clinical-stage genetic medications' thought-leader dedicated to harnessing the capabilities of genetic medicine to tackle major massive market illnesses,...


Pioneering the Future of Genetic Medicine: 4DMT and Arbor Biotechnologies Collaborate on Treating CNS Disorders

Published Wed, Jan 3 2024 1:02 PM UTC

In an outstanding demonstration of biotech synergy, 4D Molecular Therapeutics(Nasdaq: FDMT, 4DMT), a trailblazing clinical-stage genetic medicines enterprise, and Arbor Biotechnologies, Inc., an innovative gene editing firm, have announced a strategic partnership. This collaboration intends to accelerate the development of new AAV-based gene-editing therapies for central ner...


4d Molecular Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com